HUE068144T2 - A pegilált urikáz készítmények és dózisok - Google Patents
A pegilált urikáz készítmények és dózisokInfo
- Publication number
- HUE068144T2 HUE068144T2 HUE17715298A HUE17715298A HUE068144T2 HU E068144 T2 HUE068144 T2 HU E068144T2 HU E17715298 A HUE17715298 A HU E17715298A HU E17715298 A HUE17715298 A HU E17715298A HU E068144 T2 HUE068144 T2 HU E068144T2
- Authority
- HU
- Hungary
- Prior art keywords
- doses
- formulations
- pegylated uricase
- uricase
- pegylated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y107/00—Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
- C12Y107/03—Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
- C12Y107/03003—Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nanotechnology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Transplantation (AREA)
- Physical Education & Sports Medicine (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Dermatology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662307412P | 2016-03-11 | 2016-03-11 | |
| US201662339944P | 2016-05-22 | 2016-05-22 | |
| US201662346348P | 2016-06-06 | 2016-06-06 | |
| US201662397832P | 2016-09-21 | 2016-09-21 | |
| US201662398422P | 2016-09-22 | 2016-09-22 | |
| US201662403664P | 2016-10-03 | 2016-10-03 | |
| US201662430547P | 2016-12-06 | 2016-12-06 | |
| US201762442948P | 2017-01-05 | 2017-01-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HUE068144T2 true HUE068144T2 (hu) | 2024-12-28 |
Family
ID=58464628
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HUE17715298A HUE068144T2 (hu) | 2016-03-11 | 2017-03-11 | A pegilált urikáz készítmények és dózisok |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US20170258927A1 (https=) |
| EP (2) | EP3426285B1 (https=) |
| JP (3) | JP7417354B2 (https=) |
| KR (3) | KR102921105B1 (https=) |
| CN (1) | CN109152819A (https=) |
| AU (2) | AU2017230891B2 (https=) |
| BR (1) | BR112018068249A2 (https=) |
| CA (1) | CA3017365A1 (https=) |
| DK (1) | DK3426285T3 (https=) |
| ES (1) | ES2986077T3 (https=) |
| FI (1) | FI3426285T3 (https=) |
| HR (1) | HRP20241127T1 (https=) |
| HU (1) | HUE068144T2 (https=) |
| IL (2) | IL318183A (https=) |
| LT (1) | LT3426285T (https=) |
| MX (1) | MX2018011012A (https=) |
| PL (1) | PL3426285T3 (https=) |
| PT (1) | PT3426285T (https=) |
| RS (1) | RS65941B1 (https=) |
| SI (1) | SI3426285T1 (https=) |
| WO (1) | WO2017156513A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE052976T2 (hu) | 2005-04-11 | 2021-06-28 | Horizon Pharma Rheumatology Llc | Urát-oxidáz variáns formái és azok alkalmazása |
| HUP1200205A3 (en) | 2009-06-25 | 2012-09-28 | Savient Pharmaceuticals | Method and kits for perdicting infusion reaction risk and antibody-mediated low of response by monitoring serum uric acid during pegylated uricare therapy |
| WO2012061717A1 (en) | 2010-11-05 | 2012-05-10 | Selecta Biosciences, Inc. | Modified nicotinic compounds and related methods |
| KR20140041505A (ko) | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| JP2014521687A (ja) | 2011-07-29 | 2014-08-28 | セレクタ バイオサイエンシーズ インコーポレーテッド | 体液性および細胞傷害性ｔリンパ球（ｃｔｌ）免疫応答を生成する合成ナノキャリア |
| HUE052599T2 (hu) | 2013-05-03 | 2021-05-28 | Selecta Biosciences Inc | CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények |
| AU2015311704B2 (en) | 2014-09-07 | 2021-12-09 | Selecta Biosciences, Inc. | Methods and compositions for attenuating gene editing anti-viral transfer vector immune responses |
| ES2986077T3 (es) * | 2016-03-11 | 2024-11-08 | Cartesian Therapeutics Inc | Formulaciones y dosis de uricasa pegilada |
| US20200237881A1 (en) | 2019-01-30 | 2020-07-30 | Horizon Pharma Rheumatology Llc | Reducing immunogenicity to pegloticase |
| CN110234340A (zh) | 2016-11-11 | 2019-09-13 | 好利恩风湿病制药有限责任公司 | 泼尼松和尿酸酶分子的组合疗法及其用途 |
| WO2018169811A1 (en) | 2017-03-11 | 2018-09-20 | Selecta Biosciences, Inc. | Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant |
| JP2020530282A (ja) | 2017-07-07 | 2020-10-22 | アレナ ファーマシューティカルズ， インコーポレイテッド | 組換えウリカーゼ酵素 |
| CN109875988B (zh) * | 2018-09-13 | 2021-08-27 | 江西中医药大学 | 一种化合物dhnb缩氨基脲的合成及其在防治痛风与高尿酸血症的应用 |
| US12121566B2 (en) | 2019-01-30 | 2024-10-22 | Horizon Therapeutics Usa, Inc. | Methods for treating gout |
| CN114207440A (zh) * | 2019-06-04 | 2022-03-18 | 西莱克塔生物科技公司 | 聚乙二醇化尿酸酶的制剂和剂量 |
| KR102260478B1 (ko) * | 2019-08-19 | 2021-06-02 | 연세대학교 산학협력단 | 일나트륨 요소화물 결정 용해용 조성물 |
| EP4021482A4 (en) * | 2019-08-30 | 2023-04-19 | Horizon Therapeutics Ireland Dac | PEGLOTICASE FOR THE TREATMENT OF GOUT IN KIDNEY TRANSPLANT RECIPIENT |
| EP4048269A1 (en) * | 2019-10-21 | 2022-08-31 | Selecta Biosciences, Inc. | Methods and compositions for treating liver diseases and disorders |
| US20210187081A1 (en) * | 2019-11-08 | 2021-06-24 | Selecta Biosciences, Inc. | Formulations and doses of pegylated uricase |
| KR102200329B1 (ko) * | 2019-11-11 | 2021-01-08 | 광주과학기술원 | 반감기 증가를 위한 치료용 단백질-지방산 접합체 및 이의 용도 |
| MX2023001740A (es) * | 2020-08-10 | 2023-04-05 | Horizon Therapeutics Usa Inc | Metodos de tratamiento de la gota. |
| US12269875B2 (en) | 2023-08-03 | 2025-04-08 | Jeff R. Peterson | Gout flare prevention methods using IL-1BETA blockers |
| WO2025076412A1 (en) * | 2023-10-04 | 2025-04-10 | Gro Biosciences Inc. | Modified polypeptides and methods of making and uses thereof |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946929A (en) | 1983-03-22 | 1990-08-07 | Massachusetts Institute Of Technology | Bioerodible articles useful as implants and prostheses having predictable degradation rates |
| US4638045A (en) | 1985-02-19 | 1987-01-20 | Massachusetts Institute Of Technology | Non-peptide polyamino acid bioerodible polymers |
| US4806621A (en) | 1986-01-21 | 1989-02-21 | Massachusetts Institute Of Technology | Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article |
| US5736372A (en) | 1986-11-20 | 1998-04-07 | Massachusetts Institute Of Technology | Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure |
| CA1340581C (en) | 1986-11-20 | 1999-06-08 | Joseph P. Vacanti | Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices |
| US5759830A (en) | 1986-11-20 | 1998-06-02 | Massachusetts Institute Of Technology | Three-dimensional fibrous scaffold containing attached cells for producing vascularized tissue in vivo |
| US5019379A (en) | 1987-07-31 | 1991-05-28 | Massachusetts Institute Of Technology | Unsaturated polyanhydrides |
| US5010167A (en) | 1989-03-31 | 1991-04-23 | Massachusetts Institute Of Technology | Poly(amide-and imide-co-anhydride) for biological application |
| US5399665A (en) | 1992-11-05 | 1995-03-21 | Massachusetts Institute Of Technology | Biodegradable polymers for cell transplantation |
| US5512600A (en) | 1993-01-15 | 1996-04-30 | Massachusetts Institute Of Technology | Preparation of bonded fiber structures for cell implantation |
| US5514378A (en) | 1993-02-01 | 1996-05-07 | Massachusetts Institute Of Technology | Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures |
| US5565215A (en) | 1993-07-23 | 1996-10-15 | Massachusettes Institute Of Technology | Biodegradable injectable particles for imaging |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US6007845A (en) | 1994-07-22 | 1999-12-28 | Massachusetts Institute Of Technology | Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers |
| US5716404A (en) | 1994-12-16 | 1998-02-10 | Massachusetts Institute Of Technology | Breast tissue engineering |
| US6123727A (en) | 1995-05-01 | 2000-09-26 | Massachusetts Institute Of Technology | Tissue engineered tendons and ligaments |
| JP3462313B2 (ja) | 1995-08-24 | 2003-11-05 | キッコーマン株式会社 | 変異型ウリカーゼ、変異型ウリカーゼ遺伝子、新規な組み換え体ｄｎａ及び変異型ウリカーゼの製造法 |
| US6095148A (en) | 1995-11-03 | 2000-08-01 | Children's Medical Center Corporation | Neuronal stimulation using electrically conducting polymers |
| US5902599A (en) | 1996-02-20 | 1999-05-11 | Massachusetts Institute Of Technology | Biodegradable polymer networks for use in orthopedic and dental applications |
| US6258823B1 (en) | 1996-07-12 | 2001-07-10 | Ariad Pharmaceuticals, Inc. | Materials and method for treating or preventing pathogenic fungal infection |
| US5837752A (en) | 1997-07-17 | 1998-11-17 | Massachusetts Institute Of Technology | Semi-interpenetrating polymer networks |
| US6632922B1 (en) | 1998-03-19 | 2003-10-14 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| US6506577B1 (en) | 1998-03-19 | 2003-01-14 | The Regents Of The University Of California | Synthesis and crosslinking of catechol containing copolypeptides |
| US6686446B2 (en) | 1998-03-19 | 2004-02-03 | The Regents Of The University Of California | Methods and compositions for controlled polypeptide synthesis |
| JP4751556B2 (ja) | 2000-02-28 | 2011-08-17 | ジーンシーグス， インコーポレイテッド | ナノカプセルカプセル化システムおよび方法 |
| GB0025414D0 (en) | 2000-10-16 | 2000-11-29 | Consejo Superior Investigacion | Nanoparticles |
| US6913915B2 (en) | 2001-08-02 | 2005-07-05 | Phoenix Pharmacologics, Inc. | PEG-modified uricase |
| US6818732B2 (en) | 2001-08-30 | 2004-11-16 | The Regents Of The University Of California | Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers |
| DK1704585T3 (en) | 2003-12-19 | 2017-05-22 | Univ North Carolina Chapel Hill | Methods for preparing isolated micro- and nanostructures using soft lithography or printing lithography |
| JP2008512350A (ja) | 2004-07-01 | 2008-04-24 | イェール ユニバーシティ | 標的化され、そして高密度で薬物が負荷されるポリマー性物質 |
| EP2630966B1 (en) | 2007-10-12 | 2017-04-19 | Massachusetts Institute of Technology | Vaccine nanotechnology |
| CN101676291B (zh) | 2008-09-18 | 2012-05-09 | 上海海和药物研究开发有限公司 | 一类雷帕霉素碳酸酯类似物、其药物组合物及其制备方法和用途 |
| KR20140041505A (ko) * | 2011-04-29 | 2014-04-04 | 셀렉타 바이오사이언시즈, 인크. | 조절 b 세포 유도를 위한 관용원성 합성 나노운반체 |
| WO2014179771A1 (en) * | 2013-05-03 | 2014-11-06 | Selecta Biosciences, Inc. | Dosing combinations for reducing undesired humoral immune responses |
| HUE052599T2 (hu) * | 2013-05-03 | 2021-05-28 | Selecta Biosciences Inc | CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények |
| ES2977259T3 (es) | 2014-11-05 | 2024-08-21 | Cartesian Therapeutics Inc | Métodos y composiciones relacionadas con nanovehículos sintéticos con rapamicina en un estado sobresaturado estable |
| ES2986077T3 (es) * | 2016-03-11 | 2024-11-08 | Cartesian Therapeutics Inc | Formulaciones y dosis de uricasa pegilada |
-
2017
- 2017-03-11 ES ES17715298T patent/ES2986077T3/es active Active
- 2017-03-11 CN CN201780028609.1A patent/CN109152819A/zh active Pending
- 2017-03-11 BR BR112018068249-7A patent/BR112018068249A2/pt unknown
- 2017-03-11 PT PT177152980T patent/PT3426285T/pt unknown
- 2017-03-11 CA CA3017365A patent/CA3017365A1/en active Pending
- 2017-03-11 AU AU2017230891A patent/AU2017230891B2/en active Active
- 2017-03-11 RS RS20240946A patent/RS65941B1/sr unknown
- 2017-03-11 MX MX2018011012A patent/MX2018011012A/es unknown
- 2017-03-11 FI FIEP17715298.0T patent/FI3426285T3/fi active
- 2017-03-11 LT LTEPPCT/US2017/021991T patent/LT3426285T/lt unknown
- 2017-03-11 PL PL17715298.0T patent/PL3426285T3/pl unknown
- 2017-03-11 KR KR1020227029367A patent/KR102921105B1/ko active Active
- 2017-03-11 JP JP2018548079A patent/JP7417354B2/ja active Active
- 2017-03-11 HU HUE17715298A patent/HUE068144T2/hu unknown
- 2017-03-11 EP EP17715298.0A patent/EP3426285B1/en active Active
- 2017-03-11 KR KR1020187029146A patent/KR20180120753A/ko not_active Ceased
- 2017-03-11 IL IL318183A patent/IL318183A/en unknown
- 2017-03-11 SI SI201731543T patent/SI3426285T1/sl unknown
- 2017-03-11 US US15/456,520 patent/US20170258927A1/en not_active Abandoned
- 2017-03-11 EP EP24177803.4A patent/EP4445955A3/en active Pending
- 2017-03-11 HR HRP20241127TT patent/HRP20241127T1/hr unknown
- 2017-03-11 KR KR1020267002811A patent/KR20260023090A/ko active Pending
- 2017-03-11 WO PCT/US2017/021991 patent/WO2017156513A1/en not_active Ceased
- 2017-03-11 DK DK17715298.0T patent/DK3426285T3/da active
-
2018
- 2018-09-12 IL IL261700A patent/IL261700A/en unknown
-
2022
- 2022-01-27 JP JP2022011177A patent/JP7547402B2/ja active Active
-
2024
- 2024-04-15 JP JP2024065367A patent/JP2024102099A/ja active Pending
- 2024-07-15 AU AU2024204851A patent/AU2024204851A1/en not_active Abandoned
- 2024-08-29 US US18/818,714 patent/US20250090451A1/en active Pending
- 2024-10-31 US US18/933,195 patent/US20250057756A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUE068144T2 (hu) | A pegilált urikáz készítmények és dózisok | |
| IL265590B (en) | Formulations and methods for keratin treatment | |
| ZA201805805B (en) | Formulations and methods | |
| ZA201807128B (en) | Pegylated liposomes and methods of use | |
| IL256364A (en) | Pharmaceutical formulations containing tenofovir and emtricitabine | |
| EP3324967A4 (en) | PRIDOPIDINE-BASED FORMULATIONS AND USE OF THE SAME | |
| PT3380525T (pt) | Formulações farmacêuticas e métodos que as utilizam | |
| IL285928A (en) | Fulvestrant formulations and methods of using them | |
| PT3474822T (pt) | Formulações de brincidofovir | |
| IL266132A (en) | Pharmacological formulations and methods for their preparation | |
| IL263349A (en) | Compositions of polyalkylene oxide-asparaginase and methods for their preparation and use | |
| IL256400A (en) | Therapeutic uses of berberine formulations | |
| IL262745A (en) | Improved preparations containing drugs | |
| ZA201801015B (en) | Oral care compositions and methods of using the compositions | |
| EP3532052A4 (en) | DESIGN AND COMPOSITION OF CELL-STABILIZED PHARMACEUTICAL FORMULATIONS | |
| IL267279A (en) | Pharmaceutical formulations of suvorexant | |
| IL267063A (en) | Fluensulfone formulations in high concentration, their uses and processes for their preparation | |
| EP3497080A4 (en) | PHARMACEUTICAL FORMULATIONS AND THEIR USE | |
| IL258304B (en) | Oral treatment compounds and methods of using the compounds | |
| PT3664800T (pt) | Formulações terapêuticas que compreendem inibidor da cox-2 e utilizações das mesmas | |
| IL264898B1 (en) | Formulations of cysteamine and its derivatives | |
| AU2016902150A0 (en) | Formulations and therapeutic uses thereof | |
| SG11201805812QA (en) | Delayed-release formulations, methods of making and use thereof | |
| HK40002433A (en) | Fulvestrant formulations and methods of their use | |
| AU2014901940A0 (en) | Formulations and Therapeutic Uses Thereof |